Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.53 +0.28 (+0.54%)

Delayed Quote Updated: 12:24 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

38 39 Next >

Current Report: Roche Holding ↗

May 16, 2022

Roche’s price per share was $39.75 as of Friday's market close. One year ago its price was $42.20.

Via Talk Markets

The OTC Markets' Most Active Securities Welcomes New Names And Experiences A Reshuffle In April ↗

May 13, 2022

Photo by Becca on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. First-quarter 2022 market...

Via Benzinga

Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others ↗

May 11, 2022

Roche isn't the only company working on an anti-TIGIT molecule.

Via Investor's Business Daily

The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine ↗

May 11, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Genentech's Tiragolumab/Tecentriq Fails On Progression Free Survival In PD-L1-High Metastatic Lung Cancer ↗

May 11, 2022

Genentech, a unit of Roche Holdings AG (OTC: RHHBY), announced results from its Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab in PD-L1-high locally advanced or metastatic non-small cell lung...

Via Benzinga

Genentech Reports Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

May 11, 2022

From Genentech

Via Business Wire

Market Selloff ↗

May 10, 2022

In a U.S. market selloff, the strong performance of mostly foreign issues was impressive.

Via Talk Markets

Roche Releases More Evrysdi Data For Very Young Infants With SMA ↗

April 29, 2022

Via Benzinga

New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)

April 29, 2022

From Genentech

Via Business Wire

Novartis Posts Higher Q1 Earnings, Sales On Strong Sandoz, Entresto; Backs 2022 Outlook ↗

April 26, 2022

Via Benzinga

Roche's CEO Warns Russia-Ukraine War Causing Problems For Multiple Sclerosis Trials ↗

April 25, 2022

The development of Roche Holdings AG's (OTC: RHHBY) multiple sclerosis candidate fenebrutinib is negatively impacted by Russia's ongoing invasion of Ukraine.

Via Benzinga

COVID-19 Tests Boost Roche's Q1 Sales, Reaffirms FY22 Outlook ↗

April 25, 2022

Via Benzinga

EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs ↗

April 22, 2022

Via Benzinga

7 Potential Biotech Stocks Buyout Targets in 2022 ↗

April 21, 2022

Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.

Via InvestorPlace

FDA Warns Against Relying On Screening Tests For Prenatal Diagnosis ↗

April 20, 2022

The U.S. FDA is warning that noninvasive prenatal screening (NIPS) tests may provide false results, such as stating a fetus may have a genetic abnormality when the fetus was...

Via Benzinga

4 Undervalued Biotech Stocks to Add to Your Buy List ↗

April 20, 2022

These biotech stocks have seen their valuations tumble in the year-to-date sell-off. But they have the wherewithal to bounce big and generate decent, market-beating returns.

Via InvestorPlace

Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers ↗

April 16, 2022

Let’s pause to consider earlier attempts at hostile takeovers by well-respected and well-financed entities and individuals that — to ransack some Musk-worthy clichés — took off like a rocket ship but...

Via Talk Markets

Lessons For Elon Musk: 5 Notorious Failed Hostile Takeovers ↗

April 15, 2022

As any student of industry knows, Elon Musk is hardly the first person to attempt a hostile takeover.

Via Benzinga

FDA Extends Review Period For Regeneron's COVID-19 Antibody Therapy ↗

April 14, 2022

Via Benzinga

Volume Springs Back Into The OTC Markets In March – Take A Look At Some Of The Top Movers ↗

April 14, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Trading volume appears to be moving back to OTC Markets...

Via Benzinga

Read Why Pliant Therapeutics Shares Are Soaring Today ↗

April 13, 2022

Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need.

Via Benzinga

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗

April 13, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal

Via Benzinga

Healthcare Stocks Lead the Way Up as the Market Fades ↗

April 11, 2022

With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions.

Via Talk Markets

BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines ↗

April 11, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Recession Fears are Creating a Golden Opportunity for Biotech Stocks ↗

April 08, 2022

Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now.

Via InvestorPlace

How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug ↗

April 08, 2022

Only Medicare patients enrolled in specific studies will receive reimbursement.

Via Investor's Business Daily

Good and Bad stock news ↗

April 05, 2022

Microsoft is down because of an FTC investigation of its possible anti-competitive moves.

Via Talk Markets

New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis

April 04, 2022

From Genentech

Via Business Wire

SoftBank Loses Vision Fund Leader; Continues To Liquidate Portfolio ↗

April 04, 2022

Ron Fisher looked to depart as the head of SoftBank Group Corp's (OTC: SFTBY) (OTC: SFTBF) Vision Fund and Chair and director of SoftBank Investment Advisors U.S....

Via Benzinga

Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis ↗

April 04, 2022

Via Benzinga

< Previous 1 2

...

23 24 25 26 27 28 29 30 31

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.